Clinical Trial: Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Brief Summary:

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor.

The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated interferon in patients with chronic HDV infection.

Detailed Summary:
Sponsor: Aga Khan University

Current Primary Outcome: Change in HDV RNA quantitative measurements of >2 logs from baseline [ Time Frame: 24 weeks of therapy ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Aga Khan University

Dates:
Date Received: March 26, 2017
Date Started: January 2016
Date Completion: June 2017
Last Updated: April 3, 2017
Last Verified: March 2017